Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations

AIDS. 2006 Jan 2;20(1):138-40. doi: 10.1097/01.aids.0000198080.32207.3c.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antiretroviral Therapy, Highly Active / methods
  • Carbamates / therapeutic use*
  • Drug Resistance, Viral / genetics
  • Drug Therapy, Combination
  • Furans
  • Genotype
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Male
  • Mutation
  • Organophosphates / therapeutic use*
  • Prodrugs / therapeutic use
  • Sulfonamides / therapeutic use*

Substances

  • Carbamates
  • Furans
  • HIV Protease Inhibitors
  • Organophosphates
  • Prodrugs
  • Sulfonamides
  • amprenavir
  • fosamprenavir